Friday, November 20, 2026
Late edition · Updated as it breaks
Log inSubmit a story

“All the news worth catching.”

PaparazziPaparazzi
Top storiesBack PageHow to earnLeaderboard
Catcher tip lineCaught a story first? Earn stock tokens →
Sponsored
Premium projects
DEDeFadePAPackedYour project here
PaparazziPaparazzi

All the news worth catching.

Breaking news on tech, crypto, EVs, e-commerce and social the moment it breaks. Written by AI from verified reporting.

SectionsTop storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & world
EarnStart hereSubmit a storyGTA WeekHow to earnLeaderboardContestsCatcher desksTop catchers by reputationAssignmentsLeagueNews bountiesCityMy catchesRewards
MarketsLive statsProof of payoutsWhale watchDeep Scan token checksStock fundHolder perksRobinhood Chain launchesRobinhood Chain projectsList your projectPremium project pagesPartnersThe Chain Weekly
PaparazziPaparazzi InkPaparazzi Ink top writersOpinionLive coverageEvents calendarThe Back PageSuggest a Back Page storyPaparazzi on TelegramHow it worksFAQProof of workAbout usHow we score trustEditorial policyPrivacy policyCorrectionsRelease notesAdvertiseMedia kitNews APIContact
$PAPA contract · Robinhood Chain
© 2026 Paparazzi

Written by AI from verified reporting. Not financial advice.

  • Home
  • Submit
  • Earn
  • Sign in
Top storiesRobinhood ChainTech & AIE-commerceWeb3 & CryptoEV & EnergyGlobal & SocialEntertainmentGamingSportsBusiness & marketsHealth & sciencePolitics & worldWhales
Health & science
Important· 53

UW Alzheimer's tau tracer wins FDA approval after 2,200 scans

A brain imaging agent that University of Wisconsin researchers helped pioneer has won FDA approval, turning years of lab work into a clinical tool for Alzheimer's diagnosis. The tracer, MK-6240, now marketed as TAUKLARIFY, lights up tau tangles in living brains. UW generated more data on it than almost any other site in the world.

By the Paparazzi desk November 20, 2026 · 1:40 AM · wisbusiness.com · 0 views
Fact boxTrust 50/100 · Developing
What we verified
  • Original source: wisbusiness.com.
  • The source published it on Nov 20, 2026 at 1:40 AM.
What we couldn't
  • No second outlet has reported it yet. Treat it as a single-source claim.

The U.S. Food and Drug Administration has approved MK-6240, a brain imaging agent now sold as TAUKLARIFY, moving a tool Wisconsin researchers have used for years from the lab into doctors' hands. UW Health researchers were among the earliest adopters of the tracer, which makes tau protein buildup visible in a living patient's brain. Data from their studies supplied critical evidence for the approval, according to wisbusiness.com.

Alzheimer's once could only be confirmed after death, when an autopsy revealed malformed clumps of beta amyloid and tau. Researchers spent two decades chasing imaging that works on living patients, starting with a PET tracer for amyloid plaque 20 years ago and a tau tracer about a decade later. Dr. Nate Chin, medical director of the Wisconsin Alzheimer's Disease Research Center, said the combined imaging lets doctors see what's happening in the brain while the disease unfolds and make more informed treatment decisions.

Sponsored

Getting there took a small army. The Wisconsin Alzheimer's Disease Research Center, the Cyclotron Research Group in the Department of Medical Physics and the Brain Imaging Core at the Waisman Center all pitched in. The tracer carries a radioactive isotope that decays fast, so the medical school's cyclotron and nuclear physics know-how were essential to producing it on demand, often daily. Sterling Johnson, associate director of the research center, said few institutions have the infrastructure to make a tracer like this routinely, crediting the cross-campus partnership for studies that otherwise wouldn't have happened. NIH funding starting in 2017 kept the work going.

Tobey Betthauser and Bradley Christian led one of the first U.S. teams to test MK-6240 on research volunteers, with a 2018 study among the first to show it could accurately image tau pathology. A 2020 study in the journal Brain, run on 167 volunteers in the long-running Wisconsin Registry for Alzheimer's Prevention, linked rising tau and amyloid levels to declining thinking, learning and memory. To date, UW researchers have run more than 2,200 scans with the tracer across 800 to 900 volunteers and patients.

The next act is treatment. Anti-tau drugs are in development, and researchers are using tau PET imaging in clinical trials to figure out which patients might benefit and whether experimental therapies hit their target, Betthauser said. No commercial launch timeline has been announced by the companies bringing MK-6240 to market. UW Health is getting ready anyway, building a clinical tau PET program with input from geriatrics, neurology and radiology, including specialists trained to read the scans. Dr. Robert Przybelski, director of UW Health Geriatric Memory Clinics, said the teams will be positioned to fold the technology into memory clinics once it's commercially available.

TopicsMK-6240 · TAUKLARIFY · University of Wisconsin School of Medicine and Public Health · UW Health · FDA · Nate Chin · Sterling Johnson · Tobey Betthauser

Share

Source: wisbusiness.com

Written by AI from verified reporting.

More stories

  • Health & science 17:29 UTC · 25 minutes ago · phys.org · Caught by @boxlink · 1 view
    Yale team catches excitons acting like light in a one-atom-thick material
  • Health & science 16:01 UTC · 2 hours ago · hoodline.com · 1 view
    Shionogi Snags Biotech Startup in Massive $2 Billion Rare Disease Power Play
  • Health & science 11:46 UTC · 6 hours ago · finance.yahoo.com · 1 view
    Medtronic's Hugo robot clears FDA for general surgery
  • Health & science 11:31 UTC · 6 hours ago · wired.com · 1 view
    El Niño Pushes California's Coastal Waters Off the Charts, and the Storms Are Following
Catcher tip line

Caught a story we missed?

Log in and send it in. If it checks out, it runs with your name on it and you earn stock tokens. The bigger the story, the bigger the reward.

Submit a story
The newsletter

Get the paper in your inbox.

A short digest of the biggest news, plus optional breaking alerts. Free, no account needed.